Clinical Trial

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

Withdrawn Phase 3
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision
Summary
This is a randomized, open-label, phase 3 study evaluating nogapendekin alfa inbakicept (NAI) plus chemoimmunotherapy containing pembrolizumab and platinum-based chemotherapy versus chemoimmunotherapy alone as first-line treatment in patients with stage IV squamous or nonsquamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Primary endpoint is progression-free survival by RECIST v1.1 based on blinded independent central review.
Protocol Amendment History 4 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-06-23
notable Enrollment reduced: 494 -> 0 participants 2026-06-23
critical Primary endpoint(s) modified 2026-05-05
notable Primary completion pushed: 2029-04-15 -> 2029-05-15 2026-05-05
Trial Details
NCT Number NCT07524257
Lead Sponsor ImmunityBio, Inc.
Conditions NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
Start Date 2026-05-29
Primary Completion 2029-05-15 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-22